BIG PHARMA EARNINGS WATCH: BRISTOL-MYERS SQUIBB, ABBVIE, ASTRAZENECA AND PFIZER

Another Round of Big Pharma Giants Beat Wall Street Expectations In Q1 After Hiking Prices Throughout Pandemic Big Pharma giants Bristol-Myers Squibb, Pfizer

05-6-2022 Read More

DOSE OF REALITY: SENATE COMMERCE HEARING OPPORTUNITY FOR LAWMAKERS TO HOLD BIG PHARMA ACCOUNTABLE

Lawmakers Should Focus Attention on Brand Name Drug Companies’ Egregious Practices, Recommit to Market-Based Solutions to Lower Drug Prices On Thursday, May 5, the U.S. Senate Committee on

05-3-2022 Read More

BIG PHARMA EARNINGS WATCH: NOVARTIS, GLAXOSMITHKLINE, AMGEN, ROCHE

Big Pharma Giants Repeatedly Hike Prices and Continue to Beat Wall Street Expectations This week, Novartis, GlaxoSmithKline, Amgen, and Roche all reported earnings for the first quarter. All four

04-29-2022 Read More

CSRXP AD CAMPAIGN: AMERICAN PEOPLE HAVE WAITED LONG ENOUGH; CONGRESS MUST HOLD BIG PHARMA ACCOUNTABLE

Seven-Figure Campaign Calls on Lawmakers to Reject Big Pharma’s Blame Game and Deliver on Repeated Promises to Lower Prescription Drug Prices For Immediate Release Contact: Jon Conradi

04-28-2022 Read More

ICYMI: NEW SURVEY FINDS VOTERS CONTINUE TO BLAME BIG PHARMA FOR OUT-OF-CONTROL DRUG PRICES, SUPPORT CONGRESSIONAL ACTION

Patients for Affordable Drugs Now Poll Finds Vast Majority of Voters Reject Pharmaceutical Industry Rhetoric, Want Lawmakers to Hold Big Pharma Accountable A new national survey from Patients for

04-27-2022 Read More

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

J&J Beats Q1 Earnings Expectations, Announces Dividend Increase After Hiking Prices on Dozens of Brand Name Drugs This week, Johnson & Johnson kicked off the first round of Big Pharma

04-20-2022 Read More

ICYMI: THE NEW YORK TIMES EDITORIAL BOARD ENDORSES SOLUTIONS TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

Highlights How Administration and Lawmakers Can Fix Loopholes Exploited by Pharmaceutical Companies to Keep Drug Prices High A new editorial from The New York Times Editorial Board highlights how

04-18-2022 Read More

CSRXP: FINALIZED CMS COVERAGE DECISION FOR ADUHELM PROTECTS SENIORS AND TAXPAYERS FROM BIG PHARMA PRICE-GOUGING

Decision Appropriately Balances Access to Treatment with the Need for More Data on the Clinical Value for Patients For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected]

04-8-2022 Read More

BIG PHARMA WATCH: BRANDED DRUG COMPANIES MORE THAN DOUBLED PRICES FOR BLOCKBUSTER BLOOD THINNING MEDICATIONS OVER TEN YEARS

New Report Demonstrates How Brand Name Drug Companies Work in “Lockstep” to Hit Patients with Higher Prices on Life-Saving Medications In case you missed it

04-7-2022 Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.